Inside Precision Medicine June 20, 2024
IPM Staff

Carrying just one copy of a genetic variant has conferred some protection against dementia for a family at high risk of inheriting early Alzheimer’s disease, according to research that could flag new therapeutic targets for dementia.

The findings come from a South-American family of more than a thousand people who are genetically predisposed to develop Alzheimer’s disease in their 40s.

The study in the New England Journal of Medicine showed that possessing the apolipoprotein APOE3 “Christchurch variant” (APOE3Ch) delayed cognitive impairment by approximately five years.

The results follow on from an earlier study in which a female family member with two copies of this rare variant only developed mild cognitive impairment in her 70s, almost three decades after it would...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, Pharma / Biotech, Provider, Survey / Study, Trends
Cancer Therapy and The Intestinal Microbiome
Podcast #5: Doing Digital Deals in Life Sciences | Deal Structure, Terms, and Series Conclusions
GLP-1 Prescribing Shifts From Type 2 Diabetes to Obesity
A New Target To Boost Cancer Immunotherapy: LAG-3
STAT+: Biotech led by J&J veterans launches with $165 million for cancer, autoimmune therapies

Share This Article